Oruka Therapeutics (ORKA) said Friday that preclinical data on its monoclonal antibody ORKA-002 support potential extended dosing intervals and show equivalent potency to bimekizumab in plaque psoriasis.

The company said ORKA-002 demonstrated a half-life of over 30 days in non-human primates, more than three times longer than bimekizumab and indicating a human half-life of about 50 days could allow dosing once every four months while a human half-life of approximately 75 days could allow dosing twice a year.

Oruka also said ORKA-002, which is being developed to potentially treat chronic skin diseases including plaque psoriasis, exhibits comparable binding affinity and potency to bimekizumab, thus reducing development risks.

The company said it expects to conduct a clinical trial of ORKA-002 and dose the first subject in Q3.

Price: 10.25, Change: +0.18, Percent Change: +1.79